Diagnostic approaches of pneumonia for commercial-scale biomedical applications: An overview by Bakare, Olalekan Olanrewaju et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=tfls21
All Life
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tfls21
Diagnostic approaches of pneumonia for
commercial-scale biomedical applications: an
overview
Olalekan Olanrewaju Bakare , Adewale Oluwaseun Fadaka , Ashwil Klein ,
Marshall Keyster & Ashley Pretorius
To cite this article: Olalekan Olanrewaju Bakare , Adewale Oluwaseun Fadaka , Ashwil
Klein , Marshall Keyster & Ashley Pretorius (2020) Diagnostic approaches of pneumonia
for commercial-scale biomedical applications: an overview, All Life, 13:1, 532-547, DOI:
10.1080/26895293.2020.1826363
To link to this article:  https://doi.org/10.1080/26895293.2020.1826363
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Published online: 05 Oct 2020.
Submit your article to this journal 
Article views: 134
View related articles 
View Crossmark data
FRONTIERS IN LIFE SCIENCE
2020, VOL. 13, NO. 1, 532–547
https://doi.org/10.1080/26895293.2020.1826363
REVIEW
Diagnostic approaches of pneumonia for commercial-scale biomedical
applications: an overview
Olalekan Olanrewaju Bakare a,c, Adewale Oluwaseun Fadaka a,b, Ashwil Klein c, Marshall Keysterc and
Ashley Pretoriusa
aBioinformatics Research Group, Department of Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Bellville, South
Africa; bDepartment of Science and Technology/Mintek Nanotechnology Innovation Centre, Bio-labels Node, Department of Biotechnology,
Faculty of Natural Sciences, University of the Western Cape, Bellville, South Africa; cEnvironmental Biotechnology Laboratory, Department of
Biotechnology, Faculty of Natural Sciences, University of the Western Cape, Bellville, South Africa
ABSTRACT
Pneumonia remains the leading infectious cause of death among children under five years of age,
and the elderly. Several biomarkers, which have been identified for its diagnosis lack specificity, as
they couldnotdifferentiate viral frombacterial pathogensof thedisease; thesebiomarkers also fail to
establish a distinction between pneumonia and other associated diseases such as pulmonary tuber-
culosis and Human Immunodeficiency Virus (HIV). This review outlined the menace of pneumonia
disease from the statistical prevalence, clinical and immunological view, challenges with the meth-
ods used in diagnosis, and more useful information about methods of diagnosis of pneumonia with
their limitations as well. Additionally, the use of aptamers and antimicrobial peptides (AMPs) rather
than antibodies tobind and recognize receptors for diagnostics, offers several advantages over other
biomarkers shortcomings such as non-specificity.
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There is nothing more worrisome to researchers and
the international health community than the rising
incidence of mortality and major economic losses
resulting from pneumonia. Approximately 2.56 mil-
lion people die from pneumonia annually (Lin et al.
2020). In 2017, for instance, 808,694 children under
the age of five died of pneumonia, accounting for fif-
teen percent of all deaths of children in that year (Shen
et al. 2020a). There are over 1400 cases of pneumo-
nia out of every 100,000 children worldwide with the
highest incidence occurring in South Asia, West and
Central Africa (Zhu et al. 2020). Recently, the world
health organization (WHO) Child Health Epidemi-
ology Reference Group gathered that the estimated
median global cases of pneumonia is 0.28 episodes per
child year, equating to an annual of 150.7 million in
which 11–20 million of these cases are severe enough
to require hospitalization (Li et al. 2020). There is very
little progress in reducing death due to pneumonia
in children. The yearly incidence of death cases in
the elderly is also estimated at 18.2 per 1000 persons
CONTACT Adewale Oluwaseun Fadaka afadaka@uwc.ac.za.
within age 65–69 years and 52.3 cases in 1000 persons
within age 85 years and above. Huge amount is bud-
geted in billions of dollars for diseases treatment sup-
port from government and international community,
in which pneumonia expenses accounted for eighty-
one percent of annual budget (Tong et al. 2018).
Pneumonia is caused by either a virus, bacterium
or fungus and it is related with a huge morbidity and
mortality in older patients comparedwithmore youth-
ful adults (Chen et al. 2020). Those most in danger are
individuals who are under 5 years or 65 years or more;
smoke tobacco, devour a lot of liquor, or both; have
fundamental conditions, for example, cystic fibro-
sis, chronic obstructive pulmonary disorder (COPD),
asthma, or conditions that influence the kidneys, heart,
or liver; have a debilitating or impaired immune sys-
tem, for instance, because of AIDS, HIV, or malignant
growth; take prescriptions for gastroesophageal reflux
disease (GERD); have as of late recouped from a cold
or influenza infection; experience malnutrition; have
been as of late hospitalized in an emergency unit;
have been presented to specific synthetic substances
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
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or toxins (Bai et al. 2020a). A few groups are more
inclined than others to pneumonia, including Native
Alaskan or certain Native American ethnicities (Kim
et al. 2017). Despite considerable effort by health agen-
cies and organizations, mortality rates due to pneu-
monia in most developing countries are growing at an
alarming increase (Liu et al. 2018).
In the last years, the methods of detection of
these diagnostic biomarkers have been constantly
advanced, ranging from blood cultures, polymerase
chain reaction, matrix assisted laser desorption or ion-
ization time of flight, immunofiltration, turbidimet-
ric immunoassay based on latex agglutination, just to
mention a few (Eddabra and Benhassou 2018). With
these methods, it is possible to detect locally confined
bacterial infections like pneumonia. However, these
methods show false negative results for viral pneumo-
nia and patients with high titres of rheumatoid factors
may also give false results (Al-Ali and Indorf 2018).
It is therefore imperative to explore other more reli-
able methods with improved sensitivity and accuracy
towards diagnosis of pneumonia.
Due to this, efforts have been made by researchers
to fill the remaining gaps in understanding this intense
respiratory infection in children and the elderly.
Almeida and Boattini (2017) revised national-level
estimates of themorbidity, extrememorbidity, mortal-
ity, etiology and hazard factors for acute lower respira-
tory infections. This gave an evaluation of comorbidity
between childhood pneumonia and diarrhoeawith the
utilization of reviews to consider the impression of
individuals towards oral rehydration sachets, antibi-
otics, and different treatments for diarrhoea and pneu-
monia in India and Kenya; Momosaki et al. (2016)
analyzed scaling up access to oral rehydration solution
for diarrhoea and pneumonia, with reference from
verifiable involvement with low–and high–performing
nations; Wazny et al. (2013) added to this work by
surveying caregivers in Kenya to evaluate efficacy of
zinc as a treatment for diarrhoea and pneumonia.
Finally, Bhutta et al. (2013) reported on the global
action plan for childhood diarrhoea and pneumonia
and showed how research priorities were developed
resulting from this effort, among others. Despite all
these, experts have called for more diagnostic research
on the pathogens causing pneumonia and the routes
through which it is transmitted, as this is of critical
importance for treatment and prevention (Rajpurkar
et al. 2017).
Furthermore, there is continuous need to improve
the research into pneumonia diagnostics in light of
the fact that the Alexandre Project, an overall surveil-
lance study found that the worldwide pace of pneu-
mococcal macrolide resistance had ascended from
16.5_% to 21.9_% in 1996–1997 to 29_% in 1998–2000
(Rudan et al. 2005). Resistance to macrolides and flu-
oroquinolones which were originally endorsed with
the approval of levofloxacin for the treatment of pneu-
mococcal infection in 1996 have been reported, with
global pace of resistance from S. pneumonia strains
running from 4_% to 100_% (Zilberberg et al. 2017).
In the face of growing bacterial resistance, the utility
of conventional antibiotics for the treatment of pneu-
monia is strained and development of new biomarkers
for accurate and sensitive diagnosis to aid proper treat-
ment and understanding of the pathogens is essential
(Fernández-Barat et al. 2017).
Also, antigenic shift and drift are the major mech-
anisms by which viruses mutate to escape being dis-
covered (Ramirez et al. 2017). As a result of this, many
global pandemics have resulted in which a particu-
lar known virus would mutate to evade detection. Of
particular interest is the advent of COVID-19 from
SARS-CoV-2 that presents with a flu-like symptoms
causing a global pandemic which calls for more seri-
ous attention and shows how serious the menace of
pneumonia infection could be (Bai et al. 2020b).
The aim of this review is to give an overview of
bacterial and viral pneumonia, stating the difficulty in
the current diagnostic methods and biomarkers whilst
giving an insight into the discovery of new biomarkers
using bioinformatics for instance, for more accurate
search. This will allow sensitive and accurate screen-
ing procedure for differential diagnostics of the specific
pneumonia pathogens in patients for early treatment
before or after onsets of symptoms, such that they can
develop an accommodating lifestyles.
Pneumonia and pneumonitis
Pneumonia is an inflammation of the lung parenchyma
(Curbelo et al. 2017). It is derived from a Greek word,
Pneuma, which means ‘breath’. Parenchyma is the
functional part of any organwhereas stromameans the
structural part made of connective tissue. This disease
begins when the lungs parenchyma gets inflamed, and
the tiny air sacs, or alveoli, inside them, fills up with
fluid. At this point, pneumonia-causing germs then
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Figure 1. The lungs and chest X-rays showing inflammation leading to pneumonia. (A) The lung presented with inflammation (left) and
normal right lung. (B) The chest X-rays showing the normal chest with clear lungs without unusual opacification, Bacterial pneumonia
displaying focal lobar consolidation in the right upper lobe, and Viral pneumonia showing diffuse interstitial patterns in the two lungs.
settle in the alveoli and multiply, causing the lung sacs
to be filled with pus (Ngari et al. 2014). This conta-
gious disease is then spread through contact with or
the touch of shared objects, sneezing, and coughing or
even inhaled. Pneumonia is generally risky for older
adults, babies, individuals with underlying illnesses,
and those with an impaired immune system. Pneu-
monia influences kids and families everywhere in the
world however it is generally predominant in Africa
(Kalil et al. 2016) (Figure 1).
Pneumonitis is a term used to refer to a non-
infectious causes of lung inflammation as a result of
drugs, exposure to birds’ excrement or feather, and
radiation/chemotherapy treatment from cancer (Sal-
isbury et al. 2019). In other words, pneumonitis is
used to describe sudden inflammation of the lung tis-
sues without an infection whereas pneumonia results
into a gradual inflammation caused by infection either
from bacteria, viruses or fungi (Son et al. 2017). Pneu-
monitis is caused when an irritant, as aforementioned,
causes the alveoli of the lungs to become inflamed,
making oxygen difficult to cross into the bloodstream,
in which in some people, the irritant is never detected
(Bowman et al. 2018). Pneumonitis is common among
farmers who use aerosols, pesticides and during har-
vest of grains and hay; among poultry workers as a
result of exposure to droppings, feathers and other
materials; during cancer treatment using chemother-
apy and among hot tub and humidifier users (Tjalvin
et al. 2018). The most common symptoms of pneu-
monitis is shortness of breath, fatigue, weight loss, loss
of appetite and dry cough which may become chronic
if undetected, resulting in fibrosis, heart failure, res-
piratory failure and death (Sommerfeld et al. 2018).
Diagnosis of pneumonitis is carried out using imaging
teats such as chest X ray test and computerized tomog-
raphy (CT) scan, blood test, pulmonary function test
using oximeter or spirometer, bronchoscopy and sur-
gical lung biopsy (Morisset et al. 2018). Corticosteroids
and oxygen therapy are procedures used for treat-
ing chemical and hypersensitivity from pneumonitis
(Helber et al. 2018).
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Pathogenesis and symptoms of pneumonia
Pathogenesis of pneumonia
Pneumonia, in clinical term, is caused by either bac-
teria, viruses or fungi (Baral et al. 2018). Based on
this, the aetiology of pneumonia can be divided into
(i) community-acquired acute pneumonia which can
be caused by Streptococcus pneumoniae, Haemophilus
influenzae, Moraxella catarrhalis, Staphylococcus
aureus, Legionella pneumophila, Enterobacteriaceae
(Klebsiella pneumoniae and Pseudomonas spp.), (ii)
community-acquired atypical pneumonia which is
caused by Mycoplasma pneumonia, Chlymadia spp.,
Coxiella burnetti and viruses (Respiratory Syncytial
Virus, Influenzae types A and B, Adenovirus known as
SARS virus), (iii) hospital-acquired
pneumonia which is caused by Gram-negative rod,
Enterobacteriaceae spp., Staphylococcus aureus, and
Pseudomonas spp., (iv) aspiration pneumonia (means
loss of cough reflex occurring in alcoholics) which is
caused by anaerobic oral flora such as (Bacteroides, pre-
votella, Fusobacterium, Pepto-streptococcus, admixed
with aerobic bacteria), (v) chronic pneumonia which
is caused by Nocardia, Actinomyces, granulomatous,
Mycobacterium tuberculosis, atypical mycobacteria,
Histoplasma capsulatum, Coccidiodes immitis, Blasto-
myces, Dermatidis and (vi) necrotizing pneumonia and
lung abscesses caused by anaerobic bacteria with/or
without mixed infection that occurs in immune-
compromised patients as a result of Cytomegalovirus,
Pneumocystis jiroveci, Mycobacterium avium-
intracellulare, invasive Aspergillosis, invasive candidi-
asis infection (Heron 2018).
Pneumonia can result from one or more pathogens
as highlighted above but some are common than oth-
ers. The most common bacterial cause of community-
acquired pneumonia (CAP) is S. pneumoniae (DeMuri
et al. 2018) whilst influenzae viruses, followed by Res-
piratory syncytial virus are the commonest viral causes
of pneumonia which are mostly severe and often, fatal.
Fungal pneumonia can result from a condition, for
example, a valley fever, brought about by the Coc-
cidioides fungus (Viriyakosol et al. 2019). Aspiration
pneumonia which is not infectious can show when an
individual inhales food, fluids, or stomach substance
into the lungs (Dragan et al. 2018). Hospital-acquired
pneumonia can happen in patients being treated for
other conditions, for instance, those connected to a
Figure 2. Pathophysiology of pneumonia adopted from flash
share at https://www.slideshare.net/hasnahnoi/pneumonia-
38313892.
respirator, or a breathing machine (Giuliano et al.
2018).
This can be strengthened by a recent state-of-the-
art diagnostic techniques study for bacterial, viral,
and fungal infections in which 38% of a specific
pathogenwas detected for community-acquired pneu-
monia (CAP) cases. The detection of one or more
viruses was seen in 23% of cases and 11% of other
bacteria. Bacterial and viral pathogen combinations
were seen in 3% of cases with fungal and mycobac-
terial organisms accounting for 1% of cases. Human
rhinoviruses were isolated in 9% of cases and influenza
virus in 6% of cases (Jain et al. 2015). However, regard-
less of the cause, the signs and symptoms will be the
same (Figures 2 and 3).
However, only pneumonia caused by bacteria have
definitive diagnosis, necessitating differentiation of
bacterial from viral causative agents of the disease,
with the effectiveness of the drugs and vaccines against
the disease being controversial (Liu et al. 2015).
In addition, pneumonia is more severe in an
immunocompromised individual with an underlying
sickness (Messiaen et al. 2017). This is because the
immune system is a host’s defense system comprising
numerous biological structures and processes within
an organism that protects against diseases. Pathogens
can rapidly develop and adjust, and thereby avoid
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Figure 3. Pathogenesis of pneumonia disease using some bac-
terial pathogens and influenza as representative of bacterial and
viral pneumonia pathogenesis. Adapted from Brundage (2006).
detection and neutralization by the immune system
(Lee 2017). The capacity of the immune system to
respond to pathogens is reduced in both the young
and the elderly, with immune responses starting to
decrease at around 50 years of age due to immuno-
senescence (Rajpurkar et al. 2017). Underlying factors
such as obesity, alcoholism, drug abuse, and malnu-
trition are common causes of poor immune function
that can make an individual vulnerable to pneumonia
infection (Nguyen et al. 2017).
Symptoms of pneumonia
The manifestations of pneumonia can shift from gen-
tle to serious which may require hospitalization, con-
tingent upon the type of germ causing the disease,
population type, age and general well-being (Zhu
et al. 2020). The first symptoms of pneumonia for
the most part look like that of a cold or flu. The
individual at that point builds up a high fever, chills,
and cough with sputum. Other symptoms include
phlegm/sputum coughed up from lungs, quick and
difficult breathing, chest pain that generally declines
when taking a full breath, known as pleuritic pain,
quick heartbeat, fatigue and weakness, nausea and
vomiting, diarrhea, sweating, headache, muscle pain,
confusion or delirium, particularly in older adults,
dusky or purplish skin colour, or cyanosis, from inef-
fectively oxygenated blood (Torres et al. 2018). These
symptoms can differ contingent upon other funda-
mental conditions, the type of pneumonia and clinical
history (Gu et al. 2018). An X-ray can show if there
is any harm to the lungs. It is regular to speculate
pneumonia if coarse breathing, wheezing, popping,
or diminished breath sounds is noticed from listen-
ing to the chest through a stethoscope. The oxygen
levels in the blood, with an painless monitor on the
finger, called a heartbeat oximeter (Baral et al. 2018).
However, it is always advised to carry out a diagnos-
tic test to establish the status of a patient rather than a
suspicion-based judgment.
Treatment and vaccination of pneumonia
The treatment of pneumonia relies upon the type and
seriousness of pneumonia. Bacterial types of pneumo-
nia are typically treated with antibiotics, contingent
upon the kind of bacteria, while viral sorts have no
conclusive treatment yet are normally treated with
consumption of a lot of fluids, in any case, antivi-
ral drugs can be utilized in influenza (Shields et al.
2018). Fungal types of pneumonia are typically treated
with antifungal drugs (Schwartz et al. 2018). Specialists
normally recommend over-the-counter (OTC) drugs
to help deal with the symptoms of pneumonia, for
example, fever, aches, pains, and coughs (Chen et al.
2018b). It is prescribed to rest and drink a lot of liq-
uids to remain hydrated so as to disperse thick mucus
and phlegm, making it simpler to cough up. Hospi-
talization for pneumonia might be required with the
utilization of a supplemental oxygen if symptoms are
particularly awful or if an individual has a debilitated
immune system or different chronic ailments (Abbott
et al. 2018). However, effective treatment is limited by
sensitive and accurate diagnosis.
Two different vaccines exist to forestall bacte-
rial pneumonia which covers a wide assortment of
pneumococcal infections and is recommended for
both children and adults, contingent upon their
immune system capacity. Pneumococcal conjugate
antibody (otherwise called Prevnar) and pneumococ-
cal polysaccharide vaccine (known as Pneumovax) are
utilized for prevention of bacterial pneumonia (Ngari
et al. 2014; Andrews et al. 2019). Prevnar (PCV13) is
ordinarily included as a major aspect of a newborn
child’s normal vaccinations (Reglinski et al. 2018). It is
recommended for kids under 2 years, adultsmore than
65 years, and those between the ages of 2 and 64 years
with certain ailments. Pneumovax (PPSV23) is recom-
mended for kids and adults who are at expanded dan-
ger of creating pneumococcal diseases (Parker et al.
2018). This incorporates adults aged 65 years or more,
individuals with diabetes, those with terminal heart,
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lung, or kidney disease, individuals who devour a lot
of alcohol or who smoke, and those without a spleen.
Those within the range of 2 and 64 years with cer-
tain other ailments might be encouraged to have this
immunization (McLaughlin et al. 2018). Also, there
is a limitation to the use of vaccines as their efficacy
is concentrated on pneumococcal pneumonia but not
viral pneumonia (Demicheli et al. 2018). Along with
vaccinations against bacterial pneumonia, physicians
suggest frequent handwashing, covering ofmouth and
nose whilst coughing and sneezing, refraining from
smoking, eating wholesomely, normal exercise and
avoiding the sputum or cough particles of pneumonia
patients. This goes to say that vaccination might not
fully protect an individual from the disease.
Available methods for pneumonia diagnosis
with their shortcomings
The core component of pneumonia etiology is diag-
nostics which largely relies on medical history, physi-
cal examination before an order for diagnostic test is
established (Murdoch et al. 2012). The routine eval-
uation of patients for pneumonia diagnosis relies on
certain methods used for decades which are based on
microscopy and culture of respiratory tract specimens,
blood cultures, and discovery of antigens in urine and
respiratory specimens, and serological test (detection
of specific antibodies in blood). Nucleic acid detec-
tionmethods such as Polymerase chain reaction (PCR)
are now established tools in diagnostic laboratories
(Douglas 2016). The detection of a potential pathogen
from upper and lower respiratory tract of a patient
does not interpret pneumonia (Zar et al. 2017). This
is because some pneumonia pathogens may colonize
the upper airways of healthy individuals, thus a dis-
tinguishing feature of colonization from infection is
very imperative, most especially from sputum sample
(Iosifidis et al. 2018). A good method of diagnosis is
very important for early onset of treatment, decreased
resistance to antibiotics and reduced mortality. Such
method should be cheap, sensitive, and accurate and
give result in a short time (Marik and Kaplan 2003).
This section therefore attempts to introduce some of
these methods used in the diagnosis of bacterial and
viral pneumonia, giving precise account of their use
and stating their challenges which necessitate the quest
for more sensitive options.
Oldmethods used for pneumonia diagnosis
The use of microscopy and culture of sputum or res-
piratory tract specimens (e.g. Broncho alveolar lavage
fluid) and blood cultures have been used for the
diagnosis of pneumonia (Kitsios et al. 2018). The
identification of respiratory pathogens in these spec-
imens collected from the lungs provide good evi-
dence of a likely microorganism causing the pneumo-
nia. Laboratory culture of specimens can be done on
standard microbiological media such as combination
of blood, chocolate and MacConkey agars (Moreno
et al. 2018). Specimen collection should be checked
for quality before diagnosis; for instance a high-
quality expectorated sputum specimen in adult con-
tains <10 squamous epithelial cells (SECs) and >25
polymorphonuclear cells (PMNs) per low power field
(magnification ∗100) or >10 for each squamous
epithelial cells (SECs) (Para et al. 2018). Sputum anal-
ysis is a phenotypic method that can determine which
organism is causing pneumonia. A bronchoscopy is
sometimes used for this investigation (Ngari et al.
2014). A thin, flexible, and lighted tube called a bron-
choscope is passed down into the lungs. This enables
the doctor to examine directly the infected parts of the
airways and lungs.
Direct immunofluorescence microscopy and isola-
tion in cell cultures are regarded as standard diagnostic
approach for viral pneumonia. Blood culture is a phe-
notypic method that has been used for the detection of
bacterial and viral pneumonia (Kermany et al. 2018).
It is noteworthy tomention that blood tests can help to
determine locally confined bacterium and virus caus-
ing pneumonia infection (Davis et al. 2017). Blood
cultures may also reveal whether the microorganism
from the lungs has spread into the bloodstream (Kalil
et al. 2016).
Antigen detection assays has been used as point-
of-care tests for pneumonia which relies on the
discovery of suitable antigens in clinical specimens
(Wunderink et al. 2018). However, commercial assays
have only been developed for selected bacterial pneu-
monia pathogens such as Streptococcus pneumonia
and Legionella pneumophila using immunochromato-
graphic test of C-polysaccharide cell wall
antigen in urine and viral pneumonia such influenza
and Respiratory syncytial virus in respiratory spec-
imens in which results depend on the viral types
or subtypes, timing of specimen collection, specimen
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type, patient age and test comparator (Suzuki et al.
2017).
Chest X-rays are a phenotypic method that can
be used for pneumonia diagnosis and will also show
which areas of (Shen et al. 2020b) the lungs are affected
(Figure 1(b)). A computerized tomography (CT) scan
of the chest may provide more detailed information
(Amatya et al. 2018).
Recentmethods for pneumonia diagnosis
Nucleic acid detection can be used for the diagno-
sis of all pneumonia types with very low levels of
nucleic acids (Shen et al. 2020b). It does not depend
on the viability of the pathogens and can provide result
within a clinically relevant time which is not affected
by a previous antibiotic resistance genes. Commer-
cial assays are now available with nucleic acid detec-
tion and have contributed to the understanding of the
role of pathogens in the causation and microbial eti-
ology of pneumonia (Wagner et al. 2018). PCR is a
molecular method uses nucleic acid detection and it
includes quantitative (qPCR) and reverse transcrip-
tase (RT-PCR) assays which have been developed to
diagnose the majority of bacterial and viral pneumo-
nia pathogens such asMycobacteria Influenzae viruses,
Streptococcus pneumoniae and Chlamydia trachoma-
tis in blood samples (Wagner et al. 2018; Freeman
et al. 2019); and it is also replacing viral culture and
serial viral antigens titre which are deemed problem-
atic because of delay in result outcome (Freeman et al.
2019).
Apart from this, there is also a wide and useful epi-
demiological data for the use of antibody detection for
pneumonia diagnosis (Cassirer et al. 2018). Serology
has advantage over other methods such as PCR and
cultures because it is more sensitive such as the case
of a bacterial pneumonia subsequently triggered by a
viral one because the viral pathogen may no longer
be detectable in respiratory specimens by these meth-
ods (Nascimento-Carvalho et al. 2018). Immunoassay
such as enzyme-linked immunosorbent assay (ELISA)
is carried out for the diagnosis of bacterial and viral
pneumonia using a receptor protein, that is highly
purified as an antigen. For instance, the use of pneu-
molysin has been used as an antigen for Streptococcus
pneumonia for its serological diagnosis using antibod-
ies (Blanco-Covián et al. 2017).
Biomarkers used in assessment of pneumonia
severity
Measurement of biomarkers such as procalcitonin
(PCT), C-reactive protein (CRP), Soluble Trigger-
ing Receptor Expressed in Myeloid Cell-1 (STREM-
1), copeptin, pro-ANP (atrial natriuretic peptide),
adrenomedullin, cortisol and D-dimers is carried out
using particular enhanced turbidimetric assay tomon-
itor pneumonia severity index (severity scores) as well
as CURB-65 (confusion, urea, respiratory rate scores,
arterial blood pressure and age) can help decision
making processes in hospitalization referral and ICU
(Intensive Care Unit) for diagnosis, prognosis and
follow-up of treatment of pneumonia. These biomark-
ers have proven useful in diagnosis as they are pro-
duced in considerably high concentration but there
is ambiguity in their specificity towards pneumonia
as they can be produced in response to other inflam-
matory stimuli in the neuron, atherosclerotic plaques,
myocytes, and lymphocytes (Yang et al. 2018); whilst,
the mechanism regulating their syntheses at these sites
is not clearly understood (Tekerek et al. 2018). CRP,
even though being nonspecific, has proven to help
establish the etiology of some infections. A high CRP
value (100mg/L) can indicate a severe bacterial infec-
tion (Rawson et al. 2018). Streptococcus pneumoniae,
viruses, Chlamydia pneumoniae, Mycoplasma pneu-
moniae, Legionella pneumophila, and Coxiella burnetii
were detected from bronchoalveolar lavage (BAL) cul-
ture of the patients and the serumCRP values revealed:
(1) high CRP values in pneumonia patients with S.
pneumoniae or L. pneumophila; (2) increased CRP val-
ues with the severity of disease showing the use of CRP
in pneumonia prognosis; (3) the use of CRP for the
commencement of treatment procedure (Mendelson
et al. 2018). CRP values are higher in certain pathogens
than others and cannot differentiate viral from bacte-
rial pneumonia (Chen et al. 2018a). Also, CRP does
not allow for the distinguishing between all the types
of pneumonia, its sensitivity is questionable. In a sys-
tematic review published in 2005, it was stated that
‘testing forC reactive protein is neither sufficiently sen-
sitive to rule out nor sufficiently specific to rule in an
infiltrate on chest radiograph and bacterial etiology
of lower respiratory tract infection’ (Beltempo et al.
2018; Keramat et al. 2018;). However, the advantage of
CRP is that its levels can be used for the follow-up of
pneumonia as well as to evaluate patient management
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and response to antibiotic therapy (Beltempo et al.
2018).
Apart from this, PCT has been used as biomarker
for sepsis and other infection since it satisfies all
the required criteria such as (1) high specificity and
sensitivity; (2) ready measurability; (3) less expen-
sive and ready availability; (4) reproducibility; and (5)
half-life of 24 hours (Stockmann et al. 2018). How-
ever, reduced sensitivity of PCT is observed due to
its elevated concentration during non-infectious con-
ditions such as trauma, surgery, cardiogenic shock,
burns, heat, stroke, acute respiratory distress syn-
drome, infectious necrosis after acute pancreatitis, and
rejection after transplantation (Jung et al. 2008). PCT
sensitivity has been compared with CRP, interleukin-6
and interferon-alpha to detect possible bacterial CAP
infection with PCT, showing high reliabilitymore than
others in the detection of CAP (Sager et al. 2017).
However, the use of procalcitonin is difficulty in the
diagnosis of pneumonia due to its nonspecific symp-
toms and may cause delay in treatment which may
have fatal outcomes in these patients (Shehabi and
Seppelt 2008).
The concentration of TREM-1 increases during
inflammation such as sepsis and ventilator acquired
pneumonia (VAP) but not in noninfectious inflam-
matory conditions like psoriasis, ulcerative colitis, and
vasculitis (Kumar and Lodha 2018). Tejera et al. (2007)
found that serum STREM-1 is high in patients with
CAP and that the prognostic value of STREM-1 is
independent of age, other inflammatory markers such
as IL-6, pneumonia severity index, sepsis, and nutri-
tional status. The study found that patients who had
increased STREM-1 levels on admission had the worst
prognostic values.
Many biomarkers such as endotoxin,
proadrenomedullin, natriuretic peptides, endothelin-
1 precursor peptides, copeptin, and cortisol have been
linked with the diagnosis and prognosis of pneumonia
(Christ-Crain et al. 2008). These biomarkers are use-
ful in guiding culture sampling, empirical antibiotics
prescription, following the clinical course of the condi-
tion and identify those who do not respond to therapy
(Ito et al. 2017). It is good to point out that while
endotoxin is a diagnostic marker just like CRP, PCT,
and sTREM-1, the other biomarkers mentioned (i.e.
proadrenomedullin, natriuretic peptides, endothelin-
1 precursor peptides, as well as copeptin and cortisol
levels) have, up till now, only been found to be useful
as prognostic markers and may be of great help in the
risk stratification of patients.
Moreover, geneticmarkers such as single nucleotide
polymorphs (SNP) and haplotypes such as CD143
rs4340 have been linked to increased risk of
community-acquired pneumonia (CAP) (Schürch
et al. 2018). Genetic factor outcomes related to
cytokines expressionmay be influencedwhere patients
with pulmonary sepsis were found to have specific
IL-10 haplotype production with significantly higher
mortality than patients who had alternative haplotypes
(Wattanathum et al. 2005). Gene polymorphisms in
human during regulated signal transduction events
of the innate immune response, including Mal (Von
Bernuth et al. 2008), IRAK-4 (Ku et al. 2007) and
MyD88 (Khor et al. 2007), can increase the risk of
invasive bacterial pneumonia. The non-specific nature
of these human-mediated biomarkers in the diagnosis
and prognosis of the severity and etiology of pneumo-
nia necessitates the quest for new biomarkers which
are cheaper, more sensitive, accurate and specific in
nature.
Use of aptamers and antimicrobial peptides as
biomarkers for potential use in pneumonia
diagnosis
Aptamers have been designed in recent years for
the detection of many difficult-to-treat cancer types
against cancer specific proteins or whole cells (Molefe
et al. 2018) and viral or bacterial pneumonia proteins
in the serumand plasma of infected cells (Banerjee and
Jaiswal 2018). Aptamers are short sequences of either
DNA or RNA or peptide molecules that have been
identified in vitro through several methods such as
systematic evolution of ligands by exponential enrich-
ment (SELEX) process (Park 2018). For instance, DNA
aptamers probes have been used to detect S. pneumo-
nia as low as 15 CFU/ml with the aid of SELEX which
shows high specificity result against closely related
streptococci and other bacteria (Bayrac and Donmez
2018). Tat and Rev are other aptamer examples used to
recognize HIV proteins using Surface Plasmon Reso-
nance (SPR), quartz crystal microbalance (QCM) and
diamond field effect transistor (FET) techniques as
biosensors whilst over 40DNA and RNA aptamers kits
have been developed for influenza viruses (González
et al. 2016).
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Furthermore, the use of antimicrobial peptides
(AMPs), which was originally known for therapeutics,
is also becoming increasingly popular in the field diag-
nostics (Torres et al. 2019). These peptides, once in a
target microbial membrane, binds target cells through
diverse mechanisms (Demaria et al. 2017). Several
research work have been carried out on the diverse
use of these molecules in diagnostics. For instance, the
diagnostic use of cathelicidin AMP, LL-37, was carried
out in congenital pneumonia utilizing its relationship
with 25-hydroxycholeciferol where the result came out
positive with a 93_% sensitivity and 86_% specificity
(Gad et al. 2015). Another research where antimicro-
bial peptides were utilized for p24 detection in HIV,
using in silico tools such as HMMER was the work of
Tincho et al. (2016) and were validated for use in a
lateral flow device in a specific and sensitive manner
(Williams et al. 2016) (Table 1).
In silicomethods for prediction of aptamers and
antimicrobial peptides for use in pneumonia
diagnosis
It is imperative to explore other methods for the dis-
covery of AMPs and optimization of the aptamer
sequences obtained from SELEX because they might
not give the required length during their in vitro gen-
eration, thus straining their specificity and sensitivity
towards the receptors ormanipulation duringmolecu-
lar conjugation on thematrix surfaces.Many computa-
tional methods have been introduced to predict AMPs
and aptamers based on the different features such as
the binary pattern method using AntiBP server, for
prediction of antibacterial peptides (Veltri et al. 2018),
the CAMPmethods (Tucker et al. 2018), the combina-
tion of sequence alignment and the feature selection
method (Beltran et al. 2018), and the pseudo amino
acid composition method (Bhadra et al. 2018). Other
methods for predicting peptides include Support Vec-
tor Machine (SVM), quantitative matrices (QM), and
artificial neural network (ANN).
Unfortunately, AMPs have many variations in size
with the aforementioned machine learning methods
only working well on AMPs of fixed lengths (Lee et al.
2018). For the CAMPmethods (Tucker et al. 2018), the
AMPs prediction is performed using Random Forests
(RF), SVM, and Discriminant Analysis (DA) based on
all classes of full AMPs sequences while in silico tools
likemolecular docking andMolecular dynamics (MD)
simulations are used for aptamers (Sabri et al. 2019a).
The sequence alignment method enjoys high predic-
tion accuracy but it is not able to predict all sequences
(Yoshida et al. 2018). This is because the classifica-
tion concept used in the sequence alignment relies
on High Scoring Segment Pairs (HSPs) scores which
represent the similarity scores between two sequences
using BLASTP. If the test sequence has no relation-
ship with any training sequence, an HSP score cannot
be generated; thus the classification concept cannot be
performed on that particular sequence. Incorporation
of high through-put bioinformatics sequencing tech-
niques (HTS), in silico aptamer and AMPs optimiza-
tion, simulation, molecular dynamics and patterning
of libraries would help to reduce the time for aptamer
andAMPdesign, including their specificity (Kinghorn
et al. 2017).
Following the discovery of aptamers and AMPs
using in silico tools, molecular validation using in vitro
study of these biomolecules for the selective index of
the optimized forms for complex formation with the
pathogen surface receptors in kits is important for
diagnostics. Several biomarkers have been used for
the development of diagnostic kits in pharmaceuti-
cal and biotechnology industries because they have
advantages such as ease of operation, ready avail-
ability, portability and cost-effectiveness (Cho et al.
2013). The use of commercial immunoassay kits has
been used to support drug and diagnostic develop-
ment but their validation can be laborious (Nerenberg
et al. 2018). Several studies have developed lateral flow
devices for the diagnosis of pathogens such as inva-
sive Aspergillus (Thornton 2008), malaria parasites
(Tahar et al. 2013) just to mention a few. Six com-
mercially available immuno-chromatographic lateral
flow device (LFD) kits were recently tested for rabies
of the brain (Eggerbauer et al. 2016). These develop-
ments can be useful in pneumonia diagnosis, if incor-
porated with in silico design of aptamers and AMPs,
for accurate, sensitive and specific viral and bacterial
pneumonia pathogens diagnostics.
Shortcomings and benefits of themethods of
pneumonia diagnosis
Most developmental work is ongoing for the improve-
ment of the nucleic acid and antigen detection to
minimize the manual steps towards development of
point-of-care test for pneumonia diagnosis. Several
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Table 1. Summary of some biomarkers used in pneumonia diagnosis.
Biomarkers Mode of detection Strength/Sn (%) Performance Limitation References
SELEX (aptamer) PCR Not specified Stable, sensitive, accurate and
specific
Short half-life and early degradation Sabri et al. (2019b)
TLS11A (aptamer) Fluorescence
microscopy
Not specified Stable, sensitive, accurate and
specific
Short half-life and early degradation Hu et al. (2017)
Molecule1 and 8
(AMPs)
HMMER 100 Very sensitive, specific and
accurate against HIV
Low datasets input into HMMER and
proteolytic degradation of AMPs
Tincho et al. (2016)
LL-37 Culture sepsis 93 Very sensitive, accurate and
specific
Proteolytic degradation Gad et al. (2015)
Procalcitonin Turbidimetric assay 92 Sensitive, non-specific and
inaccurate




C-reactive protein Turbidimetric assay 94 Sensitive, non-specific and
inaccurate
Implicated in other diseases other than
pneumonia
Ling (2020)
Copeptin Turbidimetric assay Not specified Non-sensitive, non-specific and
inaccurate




IL-6 Immunoassay 84 Non Specific, sensitive,
inaccurate
Raised in a variety of inflammatory
syndromes and has a short half life
Zeng et al. (2020)
mHLA-DR antibody Immunoassay Not specified Accurate and specific but
non-sensitive
Cross reactivity and low sensitivity Leijte et al. (2020)
Note: Sn: sensitivity.
challenges such as specimen collection and contam-
ination from the upper respiratory tract secretions,
most especially sputum, have huge implication on the
result outcome of microscopy and cultures which can
lead to an incorrect conclusion that an upper airway
colonizer is a pneumonia pathogen. A sputum with
relatively low PMNs and high SECs indicates oropha-
ryngeal contamination. Another shortcoming of blood
culture for pneumonia diagnosis is that some patients
with pneumonia have documented bloodstream infec-
tions.
In general, blood cultures have shortcomings such
as poor sensitivity with further limitations observed
in the strength of the agglutination, which is not
indicative of the pathogen causing the pneumonia and
patients have to wait for days before getting a result.
A blood culture may also produce false negative and
false positive results as seen in patients with high titres
of rheumatoid factors which may give false-positive
results (Pulido et al. 2018). However, chest X-ray test
cannot tell what kind of germ is causing pneumonia
(Rajpurkar et al. 2017). Bronchoscopy sputum anal-
ysis has shortcoming such as poor sensitivity and is
time-consuming (Cilloniz et al. 2016).
One of the shortcomings of nucleic acid detection
in pneumonia diagnosis is lack of suitable comparator
gold standard, however, positive nucleic acid detec-
tion cannot be dismissed because of negative result
from a sensitive comparator. The role of quantitative
PCR needs to be clarified by using indices of certain
clinical significance to distinguish carriage and dis-
ease as well as false result from upper respiratory tract
infection and pneumonia. Another challenge is the
detection of multiple pathogens using multiple sensi-
tive testing methods such as multiplex PCR assays in
a single patient which can present causality problem
that requires further investigation into which one is
responsible for pneumonia or whether all pathogens
have a role in the pneumonia pathogenesis. PCR is
prone to carryover contamination during manipula-
tion and amplification of its products and it cannot
provide anything other than supplemental data for
the clinician; and there is an overwhelming lack of
data on the efficacy of this method as a diagnostic
method for other bacterial and viral pneumonia (Ahn
et al. 2016). Immunoassaymethod is time-consuming,
expensive and lacks sensitivity towards the diagno-
sis of certain bacterial and viral pathogens such as
Haemophilus influenza, Legionella pneumophila, and
Influenza A virus (Schiffner-Rohe et al. 2016). Analy-
sis of the alveolar breath using non-invasive and easily
repeatable biomarkers with minimal specimens from
blood through passive diffusion may prove pivotal in
mitigating the shortcomings of pneumonia diagnosis.
The use bioinformatics approaches offer new
insights into designing alternative diagnostic kits for
commercial use using aptamers and AMPs because a
large number of bacterial strains and viruses escape
detection with the aforementioned methods con-
tributing to their shortcomings. Aptamer and AMP
molecules are less expensive compared to antibodies
and nucleic acid detection and can be modified chem-
ically for optimum function (Jo et al. 2018). Other
benefits of AMPs and aptamers such as small size,
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homogenous structure, high density and increased
binding capacity make them potential candidates for
sensitive and accurate diagnosis of disease pathogens,
including pneumonia (Kaur 2018). The use of bioin-
formatics approach saves time and offers accuracy for
the potential discovery of more biomarkers for the
sensitive diagnosis of pneumonia and the severity of
its conditions. However, the choice and combination
of in silico methods for the prediction and design of
aptamers and AMPs remain a bottleneck in achiev-
ing expectedly high sensitivity, accuracy and speci-
ficity results to effectively utilize them for pneumonia
diagnostics.
Conclusion
This review gives insight into the diagnosis of bac-
terial and viral pneumonia with emphasis on meth-
ods and biomarkers used which would aid medical
practitioners to carry out their work effectively and
allow/enable patients to develop an accommodating
lifestyles. The incorporation of in silico design and
modelling of aptamers, as well as AMPs, as biomark-
ers would facilitate pneumonia diagnosis in an easy,
fast, and sensitive manner, due to their advantages
over the years in the field of diagnostics. This review
would also provide information for improved aware-
ness and understanding of pneumonia infection from
clinical and immunological point of view that would
eventually reduce the incidence of this disease by opti-
mizing the use and discovery of these biomarkers for
sensitive diagnosis. There is a promising perspective
towards facilitation of collaborations with industries
for sustainable investment to develop diagnostic kits
from these biomarkers which offer the prospect of
job creation and economic growth through the tech-
nologies developed from scarce-skilled fields such as
Bioinformatics and Biomedical sciences.
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